152 related articles for article (PubMed ID: 38139867)
1. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program.
Ruiz-Boy S; Pedraza A; Prat M; Salas MQ; Carcelero E; Riu-Viladoms G; Suárez-Lledó M; Monge-Escartín I; Rodríguez-Lobato LG; Martínez-Roca A; Rovira M; Martínez C; Gallego C; Urbano-Ispizua Á; Sánchez J; Marcos MÁ; Fernández-Avilés F
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139867
[TBL] [Abstract][Full Text] [Related]
2. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.
Zavras P; Su Y; Fang J; Stern A; Gupta N; Tang Y; Raval A; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1482-1491. PubMed ID: 32315708
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy.
Miyao K; Terakura S; Ozawa Y; Sawa M; Kohno A; Kasahara S; Iida H; Ino K; Kusumoto S; Kasai M; Takami A; Kurahashi S; Kajiguchi T; Morishita T; Nishida T; Murata M;
Transplant Cell Ther; 2021 Apr; 27(4):342.e1-342.e10. PubMed ID: 33836887
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.
El Haddad L; Ghantoji SS; Park AK; Batista MV; Schelfhout J; Hachem J; Lobo Y; Jiang Y; Rondon G; Champlin R; Chemaly RF
J Med Virol; 2020 Jan; 92(1):86-95. PubMed ID: 31448830
[TBL] [Abstract][Full Text] [Related]
5. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan - a retrospective database study.
Ueno R; Nishimura S; Fujimoto G; Piao Y; Takenaka K
Curr Med Res Opin; 2019 Dec; 35(12):2089-2096. PubMed ID: 31353971
[No Abstract] [Full Text] [Related]
6. A clinical study of lyophilized intravenous human immunoglobulin containing high-titer cytomegalovirus-neutralizing antibody for the treatment of cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.
Zhang P; Yang D; Tian J; Feng S; Jiang E; Han M
Ann Palliat Med; 2021 May; 10(5):5533-5540. PubMed ID: 34107701
[TBL] [Abstract][Full Text] [Related]
7. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
9. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.
Fang J; Su Y; Zavras PD; Raval AD; Tang Y; Perales MA; Giralt S; Stern A; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1937-1947. PubMed ID: 32640313
[TBL] [Abstract][Full Text] [Related]
10. [Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation].
Ma R; He Y; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Jan; 62(1):76-83. PubMed ID: 36631041
[No Abstract] [Full Text] [Related]
11. Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data.
Teschner D; Knop J; Piehl C; Junker S; Witzke O
Infection; 2022 Dec; 50(6):1543-1555. PubMed ID: 35633464
[TBL] [Abstract][Full Text] [Related]
12. Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.
Asakura M; Ikegame K; Yoshihara S; Taniguchi S; Mori T; Etoh T; Takami A; Yoshida T; Fukuda T; Hatanaka K; Kanamori H; Yujiri T; Atsuta Y; Sakamaki H; Suzuki R; Ogawa H
Int J Hematol; 2010 Sep; 92(2):351-9. PubMed ID: 20694532
[TBL] [Abstract][Full Text] [Related]
13. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
[TBL] [Abstract][Full Text] [Related]
14. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
Guo Z; Chen HR; Liu XD; Bian JM; He XP; Lou JX; Chen P; Yang K; Liu D; Zhang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):971-4. PubMed ID: 22931666
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Reusser P; Einsele H; Lee J; Volin L; Rovira M; Engelhard D; Finke J; Cordonnier C; Link H; Ljungman P;
Blood; 2002 Feb; 99(4):1159-64. PubMed ID: 11830461
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.
Foster GG; Grant MJ; Thomas SM; Cameron B; Raiff D; Corbet K; Loitsch G; Ferreri C; Horwitz M
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1597-1606. PubMed ID: 32450288
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
[TBL] [Abstract][Full Text] [Related]
20. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
